Trading Signals: IOVA Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 27, 2023)(Iovance Biotherapeutics Inc)
| IOVA latest price $5.2300 (12.59%) ($5.2300 - $5.2300) on Fri. Sep. 15, 2023. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.88% (three month average) | RSI | 36 | Latest Price | $5.2300(12.59%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | IOVA declines -2.7% a day on average for past five trading days. | Weekly Trend | IOVA declines -5.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support IOVA advance at 0% a week (0% probability) XAR(75%) SLV(71%) LQD(69%) IPO(67%) CEMB(62%) | Factors Impacting IOVA price | IOVA will decline at least -2.44% in a week (0% probabilities). XRT(-63%) TBT(-46%) USO(-37%) REMX(-26%) UUP(-71%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.44% (StdDev 4.88%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-6.89(-231.74%) | Resistance Level | $5.92 | 5 Day Moving Average | $5.46(-4.21%) | 10 Day Moving Average | $5.7(-8.25%) | 20 Day Moving Average | $5.92(-11.66%) | To recent high | -40% | To recent low | 12.6% | Market Cap | $766m | | | | Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA. |